Acurx Pharmaceuticals (ACXP) Competitors $2.01 -0.03 (-1.47%) (As of 09/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACXP vs. AYTU, INDP, AGRX, RANI, CRDF, CLLS, PBYI, NVCT, XFOR, and IVAShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Aytu BioPharma (AYTU), Indaptus Therapeutics (INDP), Agile Therapeutics (AGRX), Rani Therapeutics (RANI), Cardiff Oncology (CRDF), Cellectis (CLLS), Puma Biotechnology (PBYI), Nuvectis Pharma (NVCT), X4 Pharmaceuticals (XFOR), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Aytu BioPharma Indaptus Therapeutics Agile Therapeutics Rani Therapeutics Cardiff Oncology Cellectis Puma Biotechnology Nuvectis Pharma X4 Pharmaceuticals Inventiva Acurx Pharmaceuticals (NASDAQ:ACXP) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk. Do insiders and institutionals have more ownership in ACXP or AYTU? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 35.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, ACXP or AYTU? Acurx Pharmaceuticals has higher earnings, but lower revenue than Aytu BioPharma. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$1.18-1.69Aytu BioPharma$93.76M0.15-$17.05M-$2.63-0.91 Is ACXP or AYTU more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -14.60%. Aytu BioPharma's return on equity of -31.31% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -371.20% -219.01% Aytu BioPharma -14.60%-31.31%-7.99% Do analysts rate ACXP or AYTU? Acurx Pharmaceuticals currently has a consensus price target of $12.00, indicating a potential upside of 509.14%. Given Acurx Pharmaceuticals' higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community believe in ACXP or AYTU? Aytu BioPharma received 243 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 92.31% of users gave Acurx Pharmaceuticals an outperform vote while only 67.11% of users gave Aytu BioPharma an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1292.31% Underperform Votes17.69%Aytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Which has more volatility & risk, ACXP or AYTU? Acurx Pharmaceuticals has a beta of -1.72, meaning that its stock price is 272% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500. Does the media prefer ACXP or AYTU? In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score. Company Overall Sentiment Acurx Pharmaceuticals Neutral Aytu BioPharma Neutral SummaryAcurx Pharmaceuticals and Aytu BioPharma tied by winning 7 of the 14 factors compared between the two stocks. Ad Brownstone ResearchAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.69M$7.52B$5.49B$8.42BDividend YieldN/A4.44%4.95%4.06%P/E Ratio-1.6919.06146.5918.92Price / SalesN/A340.071,696.8483.77Price / CashN/A37.6637.1531.48Price / Book5.885.974.944.55Net Income-$14.58M$152.61M$114.79M$225.12M7 Day Performance-1.96%8.17%8.79%3.62%1 Month Performance-9.09%21.01%15.37%8.20%1 Year Performance30.72%25.66%33.02%14.57% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma0.3092 of 5 stars0.31 / 5 stars$2.58+2.4%N/A+47.2%$15.40M$107.40M-0.98160Upcoming EarningsNews CoverageINDPIndaptus Therapeutics2.798 of 5 stars2.80 / 5 stars$1.51-1.3%$12.00+694.7%-62.8%$12.89MN/A-0.856Positive NewsAGRXAgile Therapeutics1.2212 of 5 stars1.22 / 5 stars$1.51flat$5.00+231.1%-20.1%$10.35M$19.98M-0.4130Analyst ForecastNews CoverageRANIRani Therapeutics1.5235 of 5 stars1.52 / 5 stars$2.37-0.8%$11.71+394.3%-21.7%$126.58M$2.72M-1.84110News CoveragePositive NewsCRDFCardiff Oncology1.1168 of 5 stars1.12 / 5 stars$2.71+5.9%$9.67+256.7%+55.2%$126.15M$490,000.00-3.0120Gap UpCLLSCellectis3.0416 of 5 stars3.04 / 5 stars$2.25-6.3%$8.00+255.6%+40.2%$125.06M$9.19M-1.74290Analyst ForecastPositive NewsPBYIPuma Biotechnology3.263 of 5 stars3.26 / 5 stars$2.53+0.8%$7.00+176.7%-14.1%$124.10M$235.60M7.67200Gap UpNVCTNuvectis Pharma2.5545 of 5 stars2.55 / 5 stars$6.67+2.6%$21.00+214.8%-52.6%$122.44MN/A-4.738Negative NewsXFORX4 Pharmaceuticals3.9607 of 5 stars3.96 / 5 stars$0.71+4.7%$3.67+416.4%-35.1%$119.64MN/A-1.0180IVAInventiva1.2611 of 5 stars1.26 / 5 stars$2.24-0.4%$18.00+703.6%-44.6%$117.55M$17.48M0.00100Upcoming EarningsGap Down Related Companies and Tools Related Companies: Aytu BioPharma Alternatives Indaptus Therapeutics Alternatives Agile Therapeutics Alternatives Rani Therapeutics Alternatives Cardiff Oncology Alternatives Cellectis Alternatives Puma Biotechnology Alternatives Nuvectis Pharma Alternatives X4 Pharmaceuticals Alternatives Inventiva Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACXP) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACXP Stock Alerts